1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Biond Biologics Begins Phase 1 Clinical Trial, Administers First Dose of BND-35

26 Jun 2024
Admin
News Article

Biond Biologics Begins Phase 1 Clinical Trial, Administers First Dose of BND-35

Overview

Biond Biologics Ltd. (""Biond""), a clinical-stage biopharmaceutical company specializing in cancer immunotherapy, has initiated its first-in-human clinical trial of BND-35, a humanized ILT3/LILRB4 antagonist antibody. The trial commenced with the dosing of its first patient at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of six sites in Israel and the US participating in the study.

Aim for the Study

This phase 1, open-label, dose escalation study aims to assess the safety, tolerability, pharmacokinetics, and potential anti-tumor activity of BND-35 as both a standalone treatment and in combination with either a PD-1/PD-L1 inhibitor or the anti-EGFR drug cetuximab.
The decision to combine BND-35 with cetuximab was based on supportive preclinical data and a thorough understanding of its mechanism of action.
BND-35 enhances immune response through mechanisms such as antibody-dependent cellular phagocytosis and cytotoxicity, which are mediated by Fc receptors on immune cells.

Words from MS: Davidoff Center

Professor Salomon Stemmer, M.D., Head of Research, Development, and Innovation at the Davidoff Center, highlighted the trial's innovative approach in targeting the immunosuppressive tumor microenvironment (TME). He emphasized the need for novel therapies for cancers resistant to current treatments, underscoring BND-35's potential based on promising preclinical efficacy.

From Project Manager for BND-35

According to Tsuri Peretz, project manager for BND-35, the antibody blocks ILT3/LILRB4 receptors expressed on suppressive myeloid cells in the TME, thereby disrupting immunosuppression and enhancing the immune system's ability to combat tumors.
In vitro and ex vivo studies support BND-35's role in promoting a pro-inflammatory environment within the TME, crucial for boosting anti-tumor responses.

Efficacy of BND-35

BND-35's efficacy has been validated in patient-derived tumoroids and in vivo models, demonstrating reduced tumor growth and activation of tumor-resident immune cells when used alone or in combination therapy.
Further details about the trial can be found at ClinicalTrials.gov under trial identifier NCT06274437.